Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Recurrence of focal segmental glomerulosclerosis (FSGS) following kidney transplantation remains a significant cause of allograft loss. Much remains unknown about the efficacy of apheresis treatments and the factors that determine favorable treatment outcomes.
This retrospective cohort study involved adult patients who developed recurrent FSGS in the post-transplant period over six years, from January 1, 2017, to December 31, 2022. Twenty patients with biopsy-confirmed FSGS who received therapeutic apheresis as part of their treatment regimen were included. Demographic data, transplant characteristics, procedure details, urine protein levels, and other relevant variables were retrieved. Data were compiled in an Excel spreadsheet and analyzed using the Statistical Package for the Social Sciences (SPSS, IBM NY, 2023, version 29). A p-value of less than 0.05 was considered statistically significant.
Data from 20 patients encompassing 169 therapeutic apheresis sessions were analyzed. Of these, 15 patients (75%) achieved remission, while 5 (25%) did not. The median time to remission was 6 months, and the median number of apheresis sessions was 7 (interquartile range [IQR] = 2–13). There was no significant difference in time to remission between patients with complete and partial remission. Receiving more than five apheresis sessions (adjusted odds ratio [AOR] = 1.9, 95% CI = 1.5–11.5) and having lower baseline proteinuria at treatment initiation (AOR = 2.5, 95% CI = 2.3–7.9, p = 0.04) were independent predictors of remission. The complication rate was 11%, with hypocalcemia being the most common, occurring in 6% of cases. One mortality was recorded during apheresis, yielding a procedure-related mortality rate of 0.006%.
Initiating treatment at lower levels of proteinuria (i.e., earlier in the course of disease recurrence) and increasing the number of apheresis sessions appear to enhance the likelihood of remission in this cohort. The procedure was generally well tolerated, with few reversible adverse events. However, vigilant monitoring remains essential for optimal management. This abstract was also submitted for presentation at the American Society for Apheresis annual meeting in Denver, Colorado April 2026.
